

MEDIFAST INC  
Form 10-Q  
May 10, 2012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE  
X ACT OF 1934.**

For the quarter period ended March 31, 2012

OR

**.. TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT  
OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number

**Medifast, Inc.**

**(Exact name of registrant as specified in its charter)**

Delaware 13-3714405  
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

**11445 Cronhill Drive  
Owings Mills, MD 21117  
Telephone Number: (410) 581-8042**

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 16 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerate filer. See definition of "accelerated filer and large accelerated filer" in Rule 12 b-2 of the Exchange Act (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12 b-2 of the Exchange Act).

Yes  No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

| <b>Class</b>                                    | <b>Outstanding at May 9, 2012</b> |
|---|-----------------------------------|
| <b>Common stock, \$.001 par value per share</b> | <b>15,525,955</b>                 |

**Medifast, Inc.**

**Index**

Part 1 – Financial Information:

Item 1 – Financial Statements

Condensed Consolidated Balance Sheets as of March 31, 2012 (unaudited) and December 31, 2011 (audited) 3

Condensed Consolidated Statements of Income (unaudited) for the Three Months Ended March 31, 2012 and 2011 4

Condensed Consolidated Statements of Comprehensive Income (unaudited) for the Three Months Ended March 31, 2012 and 2011 5

Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) for the Three Months Ended March 31, 2012 6

Condensed Consolidated Statements of Cash Flows (unaudited) for the Three Months Ended March 31, 2012 and 2011 7

Notes to Unaudited Condensed Financial Statements 8

Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations 13

Item 3 – Quantitative and Qualitative Disclosures about Market Risk 20

Item 4 – Controls and Procedures 20

Part II – Other Information:

Item 1 – Legal Proceedings 20

Item 1-A – Risk Factors 21

Item 5 – Other Information 21

Item 6 – Exhibits 23

**MEDIFAST, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED BALANCE SHEETS**

|  | (Unaudited)<br>March 31, 2012 | (Audited)<br>December 31, 2011 |
|--|-------------------------------|--------------------------------|
| <b>ASSETS</b>  |                               |                                |
| Current assets:  |                               |                                |
| Cash and cash equivalents  | \$ 31,935,000                 | \$ 14,262,000                  |
| Accounts receivable-net of allowance for sales returns and doubtful accounts of \$518,000 and \$504,000                  | 2,177,000                     | 1,477,000                      |
| Inventory  | 15,347,000                    | 19,969,000                     |
| Investment securities  | 20,053,000                    | 19,538,000                     |
| Income taxes, prepaid  | 2,729,000                     | 5,434,000                      |
| Prepaid expenses and other current assets  | 2,836,000                     | 2,251,000                      |
| Deferred tax assets  | 690,000                       | 1,055,000                      |
| Total current assets   | 75,767,000                    | 63,986,000                     |
| Property, plant and equipment - net  | 39,193,000                    | 38,852,000                     |
| Trademarks and intangibles - net   | 896,000                       | 1,003,000                      |
| Other assets   | 1,406,000                     | 1,824,000                      |
| <b>TOTAL ASSETS</b>  | <b>\$ 117,262,000</b>         | <b>\$ 105,665,000</b>          |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>  |                               |                                |
| Current liabilities:   |                               |                                |
| Accounts payable and accrued expenses  | \$ 26,163,000                 | \$ 18,830,000                  |
| Current maturities of long-term debt and capital leases  | 1,290,000                     | 1,426,000                      |
| Total current liabilities  | 27,453,000                    | 20,256,000                     |
| Other liabilities  |                               |                                |
| Long-term debt, net of current portion   | 3,281,000                     | 3,337,000                      |
| Capital leases, net of current portion   | 836,000                       | 914,000                        |
| Deferred tax liabilities   | 7,589,000                     | 7,756,000                      |
| Total liabilities  | 39,159,000                    | 32,263,000                     |
| Stockholders' Equity:  |                               |                                |
| Preferred stock, \$.001 par value (1,500,000 authorized, no shares issued and outstanding)                               | -                             | -                              |
| Common stock; par value \$.001 per share; 20,000,000 shares authorized; 15,525,955 and 15,510,185 issued and outstanding | 16,000                        | 16,000                         |
| Additional paid-in capital   | 36,649,000                    | 36,076,000                     |
| Accumulated other comprehensive income   | 534,000                       | 396,000                        |
| Retained earnings  | 64,648,000                    | 60,658,000                     |
| Less: cost of 1,458,908 shares of common stock in treasury for both periods  | (23,744,000 )                 | (23,744,000 )                  |

Edgar Filing: MEDIFAST INC - Form 10-Q

|  |                |                |
|--|----------------|----------------|
| Total stockholders' equity                 | 78,103,000     | 73,402,000     |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | \$ 117,262,000 | \$ 105,665,000 |

See notes to unaudited condensed consolidated financial statements.

**MEDIFAST, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF INCOME****(Unaudited)**

|                                       | Three Months Ended March 31, |               |
|---------------------------------------|------------------------------|---------------|
|                                       | 2012                         | 2011          |
| Revenue                               | \$ 88,924,000                | \$ 74,295,000 |
| Cost of sales                         | 22,169,000                   | 17,614,000    |
| Gross Profit                          | 66,755,000                   | 56,681,000    |
| Selling, general, and administration  | 60,618,000                   | 46,578,000    |
| Income from operations                | 6,137,000                    | 10,103,000    |
| Other income                          |                              |               |
| Interest income/ (expense), net       | 73,000                       | 63,000        |
| Other                                 | 123,000                      | 115,000       |
|                                       | 196,000                      | 178,000       |
| Income before income taxes            | 6,333,000                    | 10,281,000    |
| Provision for income taxes            | (2,343,000 )                 | (3,923,000 )  |
| Net income                            | \$ 3,990,000                 | \$ 6,358,000  |
| Basic earnings per share              | \$ 0.29                      | \$ 0.44       |
| Diluted earnings per share            | \$ 0.29                      | \$ 0.44       |
| Weighted average shares outstanding - |                              |               |
| Basic                                 | 13,676,922                   | 14,320,959    |
| Diluted                               | 13,827,821                   | 14,598,080    |

See notes to unaudited condensed consolidated financial statements.

**MEDIFAST, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(Unaudited)**

|   | Three Months Ended March 31, |              |
|---|------------------------------|--------------|
|   | 2012                         | 2011         |
| Net income                              | \$ 3,990,000                 | \$ 6,358,000 |
| Other comprehensive income, net of tax  |                              |              |
| Unrealized gains (losses) on securities | 138,000                      | (28,000 )    |
| Other comprehensive income (loss)       | 138,000                      | (28,000 )    |
| Comprehensive income                    | \$ 4,128,000                 | \$ 6,330,000 |

See notes to unaudited condensed consolidated financial statements.

**MEDIFAST, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY****Three Months Ended March 31, 2012****(Unaudited)**

|   | Number of<br>Shares | Par Value<br>\$0.001<br>Amount | Additional Paid-<br>In Capital | Retained Earnings | Accumulated<br>other<br>Comprehensive<br>income/(loss) | Treasury Stock  | Total         |
|---|---------------------|--------------------------------|--------------------------------|-------------------|--|-----------------|---------------|
| Balance,<br>December 31,<br>2011                              | 15,510,185          | \$ 16,000                      | \$ 36,076,000                  | \$ 60,658,000     | \$ 396,000   | \$(23,744,000 ) | \$ 73,402,000 |
| Share-based<br>compensation to<br>executives and<br>directors |                     |                                | 573,000                        |                   |  |                 | 573,000       |
| Restricted shares<br>issued to<br>executives and<br>directors | 15,770              |                                |                                |                   |  |                 |               |
| Comprehensive<br>income:                                      |                     |                                |                                |                   |  |                 |               |
| Net income  |                     |                                |                                | 3,990,000         |  |                 | 3,990,000     |
| Net change in<br>unrealized gain<br>(loss) on<br>investments  |                     |                                |                                |                   | 138,000  |                 | 138,000       |
| Comprehensive<br>income                                       |                     |                                |                                |                   |  |                 | 4,128,000     |
| Balance at March<br>31, 2012                                  | 15,525,955          | \$ 16,000                      | \$ 36,649,000                  | \$ 64,648,000     | \$ 534,000   | \$(23,744,000 ) | \$ 78,103,000 |

See notes to unaudited condensed consolidated financial statements.



**MEDIFAST, INC. AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(Unaudited)**

|  | Three Months Ended March 31, |                   |
|--|------------------------------|-------------------|
|  | 2012                         | 2011              |
| Cash flows from operating activities:  |                              |                   |
| Net income   | \$ 3,990,000                 | \$ 6,358,000      |
| Adjustments to reconcile net income to net cash provided by operating activities from continuing operations: |                              |                   |
| Depreciation and amortization  | 2,381,000                    | 1,648,000         |
| Realized (gain) loss on investment securities, net   | (13,000 )                    | (115,000 )        |
| Share-based compensation   | 573,000                      | 682,000           |
| Deferred income taxes  | 111,000                      | 580,000           |
| Loss on disposal of fixed assets   | 40,000                       |                   |
| Changes in assets and liabilities which provided (used) cash:  |                              |                   |
| Accounts receivable  | (700,000 )                   | (192,000 )        |
| Inventory  | 4,622,000                    | 3,667,000         |
| Prepaid expenses and other current assets  | (585,000 )                   | (257,000 )        |
| Other assets   | 251,000                      | 4,000             |
| Accounts payable and accrued expenses  | 7,333,000                    | 3,578,000         |
| Income taxes, prepaid  | 2,705,000                    | 2,795,000         |
| Net cash provided by operating activities  | 20,708,000                   | 18,748,000        |
| Cash Flow from Investing Activities:   |                              |                   |
| Sale of investment securities  | 2,582,000                    | 3,638,000         |
| Purchase of investment securities  | (2,859,000 )                 | (5,537,000 )      |
| Purchase of property and equipment   | (2,492,000 )                 | (3,083,000 )      |
| Net cash used in investing activities  | (2,769,000 )                 | (4,982,000 )      |
| Cash Flow from Financing Activities:   |                              |                   |
| Repayment of long-term debt and capital leases   | (270,000 )                   | (239,000 )        |
| Decrease in note receivable  | 4,000                        | 2,000             |
| Excess tax benefits from share-based compensation  | -                            | 495,000           |
| Net cash provided by financing activities  | (266,000 )                   | 258,000           |
| <b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>   | <b>17,673,000</b>            | <b>14,024,000</b> |
| Cash and cash equivalents - beginning of the period  | 14,262,000                   | 17,165,000        |
| Cash and cash equivalents - end of period  | \$ 31,935,000                | \$ 31,189,000     |
| Supplemental disclosure of cash flow information:  |                              |                   |
| Interest paid  | \$ 29,000                    | \$ 25,000         |
| Income tax refunds received, net   | \$ 515,000                   | \$ -              |

See notes to unaudited condensed consolidated financial statements.

7

**Medifast, Inc.**

**Notes to Unaudited Condensed Consolidated Financial Statements**

**General**

1. Basis of Presentation

The condensed unaudited interim consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. The condensed consolidated financial statements and notes are presented as permitted on Form 10-Q and do not contain information included in the Company's annual statements and notes. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading.

The results for the three months ended March 31, 2012 are not necessarily indicative of the results to be expected for the year ending December 31, 2012 or any other portions thereof. Certain information in footnote disclosures normally included in annual financial statements has been condensed or omitted for the interim periods presented in accordance with the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim consolidated financial statements.

These financial statements do not contain all of the information and footnotes required by generally accepted accounting principles for complete financial statements. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included.

The consolidated balance sheet as of December 31, 2011 is derived from the audited financial statements included in the Company's Annual Report in Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2011 (the 2011 form 10-K), which should be read in conjunction with these consolidated financial statements.

2. Presentation of Financial Statements

The Company's condensed consolidated financial statements include the accounts of Medifast, Inc. and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

3. Recent Accounting Pronouncements

In December 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2011-11 Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, which provides for enhanced disclosures that will enable users of financial statements to evaluate the effect of netting arrangements on an entity's financial position. This includes the effect of rights of setoff associated with an entity's recognized assets and recognized liabilities. Management is currently evaluating the effect that the provisions of ASU 2011-11 will have on the Company's financial statements.

In December 2011, the FASB issued ASU 2011-12 Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05. This amendment defers changes in Update 2011-05 relating to the presentation of reclassification adjustments out of accumulated other comprehensive income. This latest amendment will allow the FASB to redeliberate the presentation requirements for reclassifications. We will evaluate the impact of this amendment when it is issued.

4. Revenue Recognition

Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid for prior to shipping. Medifast Weight Control Centers' program fees are recognized over the estimated service period.

## 5. Inventories

Inventories consist principally of packaged meal replacements held in the Company's warehouses. Inventory is stated at the lower of cost or market, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventory for unsalable or obsolete inventory.

Inventories consist of the following at March 31, 2012 and December 31, 2011:

|                | 2012         | 2011         |
|----------------|--------------|--------------|
| Raw Materials  | \$3,893,000  | \$4,591,000  |
| Packaging      | 2,073,000    | 2,204,000    |
| Finished Goods | 9,381,000    | 13,174,000   |
|                | \$15,347,000 | \$19,969,000 |

## 6. Intangible Assets

The Company has acquired certain intangible assets, which include: customer lists, trademarks, patents and copyrights. The customer lists are being amortized over a 3-year period based on management's best estimate of the expected useful life. The costs of trademarks, patents and copyrights are amortized over 3 to 5 years based on their estimated useful life.

|                                     | As of March 31, 2012     |                             | As of December 31, 2011  |                             | Weighted-Avg.<br>Amortization<br>Period |
|-------------------------------------|--------------------------|-----------------------------|--------------------------|-----------------------------|---|
|                                     | Gross Carrying<br>Amount | Accumulated<br>Amortization | Gross Carrying<br>Amount | Accumulated<br>Amortization |   |
| Customer lists                      | \$235,000                | \$148,000                   | \$235,000                | \$128,000                   | 3 years                                 |
| Trademarks, patents, and copyrights | 2,440,000                | 1,631,000                   | 2,440,000                | 1,544,000                   | 5 years                                 |
| Total                               | \$2,675,000              | \$1,779,000                 | \$2,675,000              | \$1,672,000                 |   |

Amortization expense for the three months ended March 31, 2012 and 2011 was as follows:

|                                     | 2012     | 2011     |
|-------------------------------------|----------|----------|
| Customer lists                      | \$20,000 | \$20,000 |
| Trademarks, patents, and copyrights | 87,000   | 95,000   |

Total trademarks and intangibles      \$107,000   \$115,000

Amortization expense is included in selling, general and administrative expenses.

## 7. Earnings per Share

Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of common shares outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of common shares outstanding adjusted for the effect of dilutive common stock equivalents.

The following table sets forth the computation of basic and diluted EPS for the three months ended March 31:

|   | Three Months Ended<br>March 31, |             |
|---|---------------------------------|-------------|
|   | 2012                            | 2011        |
| Numerator:  |                                 |             |
| Net income  | \$3,990,000                     | \$6,358,000 |
| Denominator:  |                                 |             |
| Weighted average shares of common stock outstanding | 13,676,922                      | 14,320,959  |
| Effect of dilutive common stock equivalents         | 150,899                         | 277,121     |
| Weighted average diluted common shares outstanding  | 13,827,821                      | 14,598,080  |
| EPS   |                                 |             |
| Basic   | \$0.29                          | \$0.44      |
| Diluted   | \$0.29                          | \$0.44      |

## 8. Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

## 9. Fair Value Measurements

Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:

## Edgar Filing: MEDIFAST INC - Form 10-Q

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management's best estimate of fair value from the perspective of a market participant.

The Company's financial instruments include cash and cash equivalents, trade receivables, investment in available-for-sale securities, and debt. The carrying amounts of cash and cash equivalents and trade receivables approximate fair value due to their short maturities. The fair value of investment in available for-sale securities are based on quoted market rates. The carrying amount of debt approximates fair value due to the variable rate associated with the debt.



The following table represents the fair value hierarchy for those financial assets measured at fair value on a recurring basis as of March 31, 2012 and December 31, 2011.

| March 31, 2012        | Level I      | Level II | Level III | Total        |
|-----------------------|--------------|----------|-----------|--------------|
| Investment securities | \$20,053,000 | -        | -         | \$20,053,000 |
| Cash equivalents      | 647,000      | -        | -         | 647,000      |
| Total Assets          | \$20,700,000 | \$ -     | \$ -      | \$20,700,000 |
| December 31, 2011     | Level I      | Level II | Level III | Total        |
| Investment securities | \$19,538,000 | -        | -         | \$19,538,000 |
| Cash equivalents      | 803,000      | -        | -         | 803,000      |
| Total Assets          | \$20,341,000 | \$ -     | \$ -      | \$20,341,000 |

10. Shared-based Compensation

Restricted Stock

The Company has issued restricted stock to employees and directors generally with terms ranging from one to six years. The fair value is equal to the market price of the Company's common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period. The following table summarizes the restricted stock activity:

|                               | Shares    | Weighed-Average<br>Grant Date Fair<br>Value |
|-------------------------------|-----------|---|
| Unvested at December 31, 2011 | 455,256   | \$ 7.08                                     |
| Granted                       | 15,770    | 17.46                                       |
| Vested                        | (80,907 ) | 7.09  |
| Forfeited                     | -         | -   |
| Unvested at March 31, 2012    | 390,119   | \$ 7.50                                     |

The total restricted stock awards vested and charged against income during the three months ended March 31, 2012 and 2011 was \$573,000 and \$682,000, respectively. The total income tax benefit recognized in the consolidated statement of income for these restricted stock awards was approximately \$223,000 and \$266,000 for the three months ended March 31, 2012 and 2011, respectively. The tax benefit recognized in additional paid-in capital upon vesting of restricted stock awards was \$0 and \$495,000 for the three months ended March 31, 2012 and 2011, respectively. There was approximately \$2.9 million of total unrecognized compensation cost related to restricted stock awards as of

March 31, 2012. The cost is expected to be recognized over a weighted-average period of approximately 1.75 years.

11.

Business Segments

Operating segments are components of an enterprise about which separate financial information is available that is regularly reviewed by the chief operating decision maker about how to allocate resources and in assessing performance. The Company has two reportable operating segments: Medifast, and MWCC and Wholesale. The Medifast reporting segment consists of the following distribution channels: Medifast Direct and Take Shape for Life. The MWCC and Wholesale segment consists of Medifast Corporate and Franchise Weight Control Centers as well as Medifast Wholesale Physicians.

Total assets and operating expense not identified with a specific segment are listed as “Other” and include items such as auditors’ fees, attorney’s fees, stock compensation expense and corporate governance related to NYSE, Sarbanes Oxley and SEC regulations. Evaluation of the performance of operating segments is based on their respective income from operations before taxes. The accounting policies of the segments are the same as those of the Company. The presentation and allocation of assets, liabilities and results of operations may not reflect the actual economic costs of the segments as stand-alone businesses. If a different basis of allocation were utilized, the relative contributions of the segments might differ, but management believes that the relative trends in segments would likely not be impacted.

Edgar Filing: MEDIFAST INC - Form 10-Q

The following tables present segment information for the three months ended March 31, 2012 and 2011:

|   | Three Months Ended March 31, 2012 |                      |                |               |
|---|-----------------------------------|----------------------|----------------|---------------|
|   | Medifast                          | MWCC &<br>Wholesales | Other          | Consolidated  |
| Revenues                                    | \$75,552,000                      | \$13,372,000         | \$-            | \$88,924,000  |
| Cost of Sales                               | 18,925,000                        | 3,244,000            | -              | 22,169,000    |
| Selling, General and Administrative Expense | 44,910,000                        | 11,837,000           | 1,489,000      | 58,236,000    |
| Depreciation and Amortization               | 1,805,000                         | 500,000              | 77,000         | 2,382,000     |
| Interest(net) and other                     | 33,000                            | 4,000                | (233,000 )     | (196,000 )    |
| Income before income taxes                  | \$9,879,000                       | \$(2,213,000 )       | \$(1,333,000 ) | \$6,333,000   |
| Segment Assets                              | \$72,802,000                      | \$14,755,000         | \$29,705,000   | \$117,262,000 |

|   | Three Months Ended March 31, 2011 |                      |                |               |
|---|-----------------------------------|----------------------|----------------|---------------|
|   | Medifast                          | MWCC &<br>Wholesales | Other          | Consolidated  |
| Revenues                                    | \$66,097,000                      | \$8,198,000          | \$-            | \$74,295,000  |
| Cost of Sales                               | 15,755,000                        | 1,859,000            | -              | 17,614,000    |
| Selling, General and Administrative Expense | 38,603,000                        | 4,948,000            | 1,379,000      | 44,930,000    |
| Depreciation and Amortization               | 1,318,000                         | 248,000              | 82,000         | 1,648,000     |
| Interest(net) and other                     | 7,000                             | -                    | (185,000 )     | (178,000 )    |
| Income before income taxes                  | \$10,414,000                      | \$1,143,000          | \$(1,276,000 ) | \$10,281,000  |
| Segment Assets                              | \$69,430,000                      | \$9,831,000          | \$26,255,000   | \$105,516,000 |

12.

Contingencies

The Company has assessed certain non-income tax contingencies in accordance with ASC 450, Accounting for Contingencies, that management believes could be challenged by tax authorities. During the ordinary course of business, there are many transactions for which the ultimate tax determination is uncertain. These potential exposures result from the varying application of statutes, rules, regulations and interpretations. Our assessment reflects assumptions and judgments about potential actions by taxing jurisdictions. We believe these assumptions and judgments are reasonable; however, our assessment of tax exposures in the future due to new developments may alter our current position on loss contingencies. A successful assertion by one or more states regarding taxes could result in substantial tax liabilities and have a material impact on operating results or cash flows in the periods for which that determination is made.

The Company from time to time is involved in legal proceedings and claims arising in the ordinary course of business. Although it is not possible to determine the outcome of these matters, it is management's opinion that settlement of such claims will not have a material adverse effect on the Company's financial condition or results in operations.

On March 17, 2011, a class action complaint titled *Oren Proter et al. v. Medifast, Inc. et al.* (Civil Action 2011-CV-720[BEL]), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and Rule 10b-5 promulgated under the Exchange Act, was filed for an unspecified amount of damages in the US District Court, District of Maryland. The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material adverse facts regarding the Company's business, operations and prospects. On March 24, 2011, a class action complaint titled *Fred Greenberg v Medifast, Inc., et al* (Civil Action 2011-CV776 [BEL], alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act, was filed for an unspecified amount of damages in the US District Court, District of Maryland. The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material adverse facts regarding the Company's business, operations and prospects. On July 19, 2011, the US District Judge ordered the consolidation of the cases and appointment of co-lead counsel among other matters. The Greenberg case was dismissed without prejudice. The Plaintiffs subsequently filed an Amended Complaint. The Company has reviewed its allegations, subsequently filed its Motion to Dismiss which is currently pending; and intends to vigorously defend against that Complaint.

As reported in the Company's Form 10-Q for the first quarter of 2011, on April 1, 2011, a shareholder derivative complaint titled *Shane Rothenberger, derivatively on behalf of Medifast, Inc., v Bradley T. MacDonald et al.* (Civil Action 2011-CV 863 [BEL]); and on April 11, 2011, a shareholder derivative complaint titled *James A. Thompson, derivatively on behalf of Medifast, Inc., v Bradley T. MacDonald et al.* (Civil Action 2011-CV934 [BEL]) were filed in the US District Court, District of Maryland. The identically worded complaints allege breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. Each complaint requests an unspecified amount of damages, a Court Order directing reformation of corporate governance, restitution to the Company and payment of costs and disbursements. The Company is named as a nominal defendant. On July 19, 2011, the US District Judge ordered consolidation of the two cases, appointment of co-lead counsel, and the filing of a consolidated complaint, among other matters. No response is due from the Company at this time. After the consolidated complaint is filed, the Company intends to take whatever action it deems necessary to protect its interests.

In early 2010, the Chapter 7 Bankruptcy Trustee for Go Fig, Inc. et al., Debtors, filed an adversary civil proceeding in the US Bankruptcy Court (ED, Missouri) against Jason Pharmaceuticals, Inc., a subsidiary of Medifast, Inc. (MED-NYSE), and other unrelated entities seeking to recover, as to each, alleged preferential payments. Jason Pharmaceuticals sold product received by the Debtors and has previously filed a pending claim in the same bankruptcy. Medifast disputes the Trustee's allegations and intends to vigorously defend itself. This action was by Court order placed on hold while the Trustee litigates similar issues against another Party.

Since 2010, Jason Pharmaceuticals has received five Notices of Charge of Discrimination filed with the US EEOC alleging discrimination suffered by 2 current employees and 3 former employees. The EEOC dismissed three of those charges in 2011. As reported in 2011 Q3, the two Claimants whose charge claims were dismissed during the second quarter filed suit to pursue those claims in US District Court. One of those claims has been resolved through mediation recently. The Company intends to vigorously defend against the remaining claim.

## **Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.**

### **FORWARD LOOKING STATEMENTS**

Some of the information presented in this quarterly report constitutes forward-looking statements within the meaning of the private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about management's expectations for fiscal year 2012 and beyond, are forward-looking statements and involve various risks and uncertainties. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge, there can be no assurance that actual results will not differ materially from the Company's expectations. The Company cautions investors not to place undue reliance on forward-looking statements which speak only to management's experience on this data.

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.

### **Critical Accounting Policies and Estimates**

Our consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles. Our significant accounting policies are described in Note 2 of the consolidated financial statements filed on Form 10-K.

The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. Management considers the following accounting estimates to be the most critical in preparing our consolidated financial statements. These critical accounting estimates have been discussed with our Audit Committee.

**Revenue Recognition:** Revenue is recognized net of discounts, rebates, promotional adjustments, price adjustments, and estimated returns and upon transfer of title and risk to the customer which occurs at shipping (F.O.B. terms). Upon shipment, the Company has no further performance obligations and collection is reasonably assured as the majority of sales are paid for prior to shipping. Medifast Weight Control Centers program fees are recognized over the estimated service period.

**Impairment of Fixed Assets and Intangible Assets:** We continually assess the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Judgments regarding the existence of impairment indicators are based on legal factors, market conditions and our operating performance. Future events could cause us to conclude that impairment indicators exist and the carrying values of fixed and intangible assets may be impaired. Any resulting impairment loss would be limited to the value of net fixed and intangible assets.

**Income Taxes:** The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

We evaluated our tax positions and determined that we did not have any material uncertain tax positions requiring recognition of a liability. Our policy is to recognize interest and penalties accrued on uncertain tax positions as part of income tax expense. For the three months ended March 31, 2012 and 2011, no material estimated interest or penalties were recognized for the uncertainty of certain tax positions. We file income tax returns in the United States and various states jurisdictions. With few exceptions, we are no longer subject to U.S. federal, state and local income tax examinations by tax authorities for the years before 2008.

**Reserves for Returns:** We review the reserves for customer returns at each reporting period and adjust them to reflect data available at that time. To estimate reserves for returns, we consider actual return rates in preceding periods. To the extent the estimate of returns changes, we will adjust the reserve, which will impact the amount of product sales revenue recognized in the period of the adjustment. Our estimates for returns have not differed materially from our actual returns. The provision for estimated returns as of March 31, 2012 and December 31, 2011 were \$285,000 and \$234,000, respectively.

Operating leases: Medifast leases retail stores, distribution facilities, and office space under operating leases. Many lease agreements contain tenant improvement allowances, rent holidays, rent escalation clauses and contingent rent provisions. The Company recognizes incentives and minimum rental expenses on a straight-line basis over the terms of the leases. We commence recording rent expense on the date of initial possession, which is generally when we enter the space and begin to make improvements to properties for our intended use. For tenant improvement allowances and rent holidays, we record a deferred rent liability on the consolidated balance sheets and amortize the deferred rent over the terms of the leases as reductions to rent expense on the consolidated statements of income.

For scheduled rent escalation clauses during the lease terms or for rental payments commencing at a date other than the date of initial occupancy, we record minimum rental expenses on a straight-line basis over the terms of the leases on the consolidated statements of income. Several leases provide for contingent rents, which are determined as a percentage of gross sales in excess of specified levels. We record a contingent rent liability on the consolidated balance sheets and the corresponding rent expense when we determine achieving specified levels is probable.

**Background:**

The Company is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The Company's product lines include meal replacements and vitamins. Our products and services are sold to weight loss program participants primarily via the Internet, telephone, and brick and mortar clinics. Customers of our Health Coaches in the Take Shape for Life person-to-person direct sales channel are directed to order our products through either the internet or through the Company's in-house call center. Our meal food items accounted for 95% of our revenues in the first quarter of 2012 and 93% of our revenues in the first quarter of 2011. Program sales in our Medifast Weight Control Center channel accounted for 3% of revenues in the first three months of 2012 and 2% in the first three months of 2011. Shipping revenue and other accounted for 2% in the first three months of 2012 and 5% in the first three months of 2011. Revenue consists primarily of meal replacement food sales. In the first three months of 2012, revenue increased to \$88.9 million as compared to \$74.3 million in the first three months of 2011, an increase of \$14.6 million or 20%. The Take Shape for Life sales channel accounted for 59.6% of total revenue, direct response marketing 25.4%, and Medifast Weight Control Centers and Medifast Wholesale Physicians 15.0%.

We review and analyze a number of key operating and financial metrics to manage our business, including revenue to advertising spend in the Medifast Direct channel, number of active Health Coaches, and average monthly revenue generated per health coach in the Take Shape for Life channel, and average same store sales improvement for the Medifast Weigh Control Center channel.

In the first three months of 2012, we continued to see sales growth and improvement in Take Shape for Life, Medifast Direct and Medifast Weight Control Centers and Medifast Wholesale Physicians. Take Shape for Life revenue increased 12% to \$53 million compared with \$47.1 million in 2011. Growth in revenues for the segment was driven



by increased customer product sales as a result of an increase in active Health Coaches. The number of active Health Coaches at the end of the first quarter of 2012 increased to 10,200 compared with 10,000 during the period a year ago, an increase of 2%. Active Health Coaches are defined as Health Coaches receiving income from a product sale in the last month of the quarter. The average revenue per health coach per month increased from \$1,600 in the first quarter of 2011 to \$1,650 in the first quarter 2012. The increase is primarily due to an increase in usage of our newly streamlined Trilogy Training website that was launched at the Take Shape for Life annual conference in late July 2011, offering easier to access training material. In addition, Take Shape for Life launched incentives in the months of February and March 2012 that drove client and coach acquisition and resulted in monthly revenue per health coach increase.

The Company is currently working on additional content for the training website and simplifying existing printed materials to maximize the effectiveness of the Health Coaches by emphasizing the competencies required to be a successful health coach, business coach and business leader. The Company is also focusing on regional events throughout the country to ensure participating Health Coaches receive actionable and relevant content to enhance and grow their business. As the number of active Health Coaches increase, the Company receives additional sales proceeds from product referrals.

The Medifast Direct Sales division increased 19% to \$22.5 million as compared with \$19 million in 2011, an increase of \$3.6 million. The Company experienced an improved revenue to spend ratio in the first quarter of 2012 of 2.9 to 1 return on advertising spend as compared to 2.8 to 1 in the first quarter of 2011.

The Medifast Weight Control Centers and Medifast Wholesale Physicians experienced revenue growth of 63% in the first quarter of 2012 as compared to 2011. Revenue increased due to the opening of thirty-one new centers in 2011, five new centers in the first quarter of 2012, as well as a 21% increase in the same store sales for Centers open for greater than one year, and the increased success of franchise centers. The Company's key focus the remainder of 2012 is continuing to enhance the customer experience through additional offerings such as metabolic testing, the support of a dietitian, and a medical review of laboratory tests to show members the impact of weight loss on their overall health. In order to improve profitability the Company is focused on reducing advertising spend as a percentage of sales for each Corporate Center, as well as realigning our four-wall staffing strategy of each Corporate Center and the amount of corporate support required to support the Medifast Weight Control Centers.

As our sales divisions grow, there are increasing demands placed upon our infrastructure. Increased demand could cause long hold times in the call center, as well as delays on our website. There could also be delays in order processing, packaging and shipping. We could run out of a majority of our inventory if product sales growth exceeds our production capacity. In order to mitigate these risks, in 2012, a key focus for infrastructure growth is expanding the Company's in-house manufacturing capacity and warehouse management systems in order to handle increased sales volumes. The Company opened a new Distribution Center in July 2010 to better service our Midwest to West Coast customers, and increase the number of orders the Company can ship daily. The Company also launched a new web platform for its sales divisions in March 2011, and added a call center location to handle additional volume.

There is also risk our independent contractor field leaders and Health Coaches could leave the Company for better opportunities, resulting in decreased revenue in the Take Shape for Life channel. This risk is mitigated by a compensation program that fairly rewards Health Coaches supporting their clients' weight loss and health goals, and increases revenue per month as Health Coaches build their organizations.

## Overview of the Company

### Distribution Channels

**Medifast Direct** – In the direct-to-consumer channel (“Medifast Direct”), customers order Medifast product directly through the Company’s websites, [www.choosemedifast.com](http://www.choosemedifast.com) and [www.medifastnow.com](http://www.medifastnow.com) or our in-house call center. The product is shipped directly to the customer’s home. This business is driven by an aggressive multi-media customer acquisition strategy that includes both national and regional print, radio, web advertising, direct mail, and television as well as public relations, word of mouth referrals, and social media initiatives. The Medifast Direct division focuses on targeted marketing initiatives and provides customer support through its in-house call center and nutrition support team of registered dietitians to better serve its customers. In addition, Medifast continues to use leading web technology featuring customized meal planning and web community components. MyMedifast is a robust online community which provides a library of support articles, scheduled weekly medical support calls, support forums, meal-planning tools, and social media functions. See Note 11, “Business Segments” of the financial statements for a detailed breakout of revenues, profit or loss, and total assets of each of the Company’s business segments.

**Take Shape For Life™**—Take Shape For Life is the personal coaching division of Medifast. Take Shape for Life is led by its co-founder, a physician with a background in critical care. The coaching network consists of independent contractor Health Coaches (“Health Coaches”), who are trained to provide coaching and support to clients on the Medifast weight-loss program. Health Coaches are conduits to give clients the encouragement and mentoring to assist them to successfully reach a healthy weight. Take Shape For Life provides a road map to empower the individual to take control of their health through better habits. Take Shape for Life offers the exclusive BeSlim® philosophy, which encourages long-term weight maintenance. Take Shape For Life also moves beyond the scope of weight loss to teach customers how to achieve optimal health through the balance of body, mind, and finances. Take Shape For Life uses the high-quality, medically validated products of Medifast that have been proven safe and effective in clinical studies. Health Coaches and their clients follow the Habits of Health book and companion workbook written by the Take Shape For Life co-founder to create a lifelong health optimization program. In addition to the encouragement and support of a Health Coach, clients of Take Shape For Life are offered a bio-network of support including website information, scheduled program medical and general support calls, and access to registered dietitians via toll-free telephone, email, and web chats.

Program entrants are encouraged to consult with their primary care physician to determine the Medifast program that is right for them. Health Coaches are required to become qualified based upon testing of their knowledge on Medifast

products and programs. Health Coaches may also become certified by The Health Institute, a proprietary training program developed by Medifast professionals. Our Health Coaches provide coaching and support to their Clients throughout the weight-loss and weight-maintenance process. Most new Health Coaches are recruited by an existing Health Coach. The vast majority of our new Health Coaches started as weight-loss clients of a Health Coach, had success on the Medifast product and program, and become a Health Coach to help others through the weight-loss process and are paid for the support services that they provide to their clients. In addition, in the Take Shape For Life network, approximately 20% of active Health Coaches are health care providers.

Health Coaches can earn compensation in two ways:

**Commissions:** The primary way a Health Coach is compensated is through earning commissions on products purchased from the company by their clients. Health Coaches earn commissions by referring product sales through their own replicated website or through the Company's in-house call center. The clients of Health Coaches are responsible for ordering and paying for product, and their order is shipped directly from the Company to the client's home or designated address. Our Health Coaches do not handle payments and are not required to purchase or store product in order to receive a commission. In addition, Health Coaches do not receive a commission on their product orders for their personal use. Health Coaches pay the same price for products as their clients. The Company pays retail commissions on a weekly basis.

**Bonuses:** Health Coaches are offered several bonus opportunities, including growth bonuses, generation bonuses, elite leadership bonuses, rolling consistency bonuses, client acquisition bonuses, and customer assist bonuses. The purposes of these bonuses are to reward Health Coaches for successfully referring product sales to the Take Shape For Life network, and to incentivize Health Coaches to further develop Health Coaches within their network. The Company pays bonuses on a monthly basis.

Growth bonuses are paid to Health Coaches that have at least five ordering clients per month and that have generated over \$1,000 in product sales per month. Monthly growth bonuses are incremental bonuses that enable Health Coaches to earn income on product orders placed by clients or Health Coaches within their network.

Generation bonuses are paid to Health Coaches that have one or more Health Coaches in their business that have achieved the rank of Executive Director. An Executive Director is a Health Coach that either generates \$6,000 a month in frontline product sales to either Clients or personally sponsored Health Coaches or personally sponsors five senior Health Coaches. A senior Health Coach is a Health Coach that generates at least \$1,000 a month in group product sales from a combination of at least five personally enrolled, ordering Clients, and/or Health Coaches, Health Coach teams, or a combination of both.

Elite leadership bonuses are paid to Health Coaches that have three or more Health Coaches in their business that have achieved the rank of Executive Director.

Rolling consistency bonuses are paid to Health Coaches that display frontline product sales order consistency month after month. Health Coaches that generate at least \$2,000 or more in frontline product sales for three consecutive months are paid a rolling consistency bonus.

Client acquisition bonuses are paid out to new Health Coaches that within their first 30 calendar days in Take Shape For Life develop five Clients and \$1,000 in frontline product sales.

The assist bonuses are paid to Health Coaches that assist a new Health Coach in their business attain the Client acquisition bonus.

Health Coaches do not earn a commission or bonus when they recruit a new Health Coach into the Take Shape For Life network. Fees paid by new Health Coaches for start-up materials are at the Company's approximate cost and no commissions are paid thereon.

Take Shape For Life is a member of the Direct Selling Association (DSA), a national trade association representing over 200 direct selling companies doing business in the United States. To become a member of the DSA, Take Shape For Life, like other active DSA member companies, underwent a comprehensive and rigorous one-year Company review by DSA legal staff that included a detailed analysis of its Company business-plan materials. This review is designed to ensure that a Company's business practices do not contravene DSA's Code of Ethics. Compliance with the requirements of the Code of Ethics is paramount to become and remain a member in good standing of DSA. Accordingly, we believe membership in DSA by Take Shape For Life demonstrates its commitment to the highest standards of ethics and a pledge not to engage in any deceptive, unlawful, or unethical business practices. Among those Code of Ethics proscriptions are pyramid schemes or endless chain schemes as defined by federal, state, or local laws. Moreover, Take Shape For Life, like other DSA member companies in good standing, has pledged to provide consumers with accurate and truthful information regarding the price, grade, quality, and performance of the products Take Shape For Life markets. See Note 11, "Business Segments" of the financial statements for a detailed breakout of revenues, profit or loss, and total assets of each of the Company's business segments.

**Medifast Weight Control Centers** – The Medifast Weight Control Center is the brick and mortar clinic channel of Medifast with locations in Pennsylvania, New Jersey, Delaware, Texas, Florida, Maryland and Virginia. In the first quarter of 2012, the Company opened five new Medifast Weight Control Centers and had a total of seventy-five locations in operation at March 31, 2012. The centers offer a high-touch model including comprehensive Medifast programs for weight loss and maintenance, customized patient counseling, and Inbody™ composition analysis. Medifast Weight Control Centers conduct local advertising including radio, print, television and web initiatives. The centers also benefit from the nationally advertised brand which encourages walk-ins and referrals from its customers and other Medifast business channels.

In 2008, the Company began offering the clinic model as a franchise opportunity. The Company currently has franchisee centers located in Alabama, Arizona, California, Louisiana, Minnesota, Maryland, Wisconsin and Pennsylvania. At March 31, 2012, 32 franchise locations were in operation.

Medifast currently offers the Medifast Weight Control Center franchise opportunity in all States except Hawaii, North Dakota, South Dakota, and Wisconsin under an approved franchise disclosure document (FDD). The FDD requires a successful applicant to develop a minimum of three Medifast Weight Control Centers within a defined geographic area in the time frame set forth in the area development agreement between Medifast and the franchisees.

Our franchise strategy depends upon on our franchisees' active involvement in and management of Medifast Weight Control Center operations. Candidates are reviewed for appropriate operational experience and financial stability, including specific net worth and liquidity requirements. Upon franchisee approval, they shall promptly select sites for the Centers and shall request Franchisor's approval of such selection based on guidelines, terms, and conditions.

A franchisee's initial fee covers the cost of Company resources provided to train applicant and staff, and determine territory for development. If a successful applicant desires to open more than three centers in the designated territory, there is an additional fee for each location over the three to be developed. The Company provides initial investment estimates in the FDD and cautions applicants considering the franchise opportunity that their actual expenses may vary from the estimates given. Legal disclosures are given and the applicant cannot sign the Agreement until he/she has had 14 days to consider the FDD.

Prior to the opening of each Medifast Center franchise established under the area development agreement, the Company will do the following:

- i. designate the Center's Protected Territory.
- ii. if the Company has not already approved a site that the franchisee has selected before signing the Franchise Agreement, designate the area within which the franchisee will locate the Center and approve the site the franchisee has selected for the location of the Center.
- iii. if the Company has not already approved a site before signing the Franchise Agreement, review and approve the franchisee lease or purchase agreement for the site for the approved location.
- iv. provide the franchisee with standard plans and specifications for the build-out of the Center along with a list of equipment and improvements which the franchisee is required to purchase and install.

v. provide an initial training program.

vi. provide the franchisee on-site assistance and guidance for approximately three to five days during or close to the opening of the Center.

vii. provide the franchise with online access to a password-protected, electronic version of the Medifast Weight Control Centers® Franchise Operations Manual.

No products or equipment are provided at a discounted purchase price. In addition, the Company does not offer direct or indirect financing. We do not guarantee franchisee's notes, leases or obligations.

**Medifast Wholesale Physicians** - Medifast physicians have been implementing the Medifast Program within their practice or clinic since 1980. These physicians carry an inventory of wholesale Medifast products and resell them to patients. They also provide appropriate medical monitoring, testing, and support for patients on the Medifast Program. Management estimates that more than 20,000 physicians nationwide have recommended Medifast as a treatment for their overweight patients since 1980, and over an estimated 1 million patients have used products at the recommendation of Medifast physicians to lose and maintain their weight. Many Medifast physicians take advantage of the Medifast Direct or the Take Shape For Life program to support their patient base.

The Company offers an additional in-house support program to assist customers that are consulting their primary care physician. Customers have access to registered dietitians that provide program support and advice via a toll-free telephone help line, by email, and online chats. See Note 11, "Business Segments" of the financial statements for a detailed breakout of revenues, profit or loss, and total assets of each of the Company's business segments.

#### Overview of the Three Months Ended March 31, 2012 Compared to Three Months Ended March 31, 2011

|  | Three Months Ended March 31, |              |              |          |
|--|------------------------------|--------------|--------------|----------|
|  | 2012                         | 2011         | \$ Change    | % Change |
| Revenue                                    | \$88,924,000                 | \$74,295,000 | \$14,629,000 | 20 %     |
| Cost of sales                              | 22,169,000                   | 17,614,000   | 4,555,000    | 26 %     |
| Gross Profit                               | 66,755,000                   | 56,681,000   | 10,074,000   | 18 %     |
| Selling, general, and administrative costs | 60,618,000                   | 46,578,000   | 14,040,000   | 30 %     |
| Income from operations                     | 6,137,000                    | 10,103,000   | (3,966,000 ) | -39 %    |
| Other income                               |                              |              |              |          |
| Interest income (expense), net             | 73,000                       | 63,000       | 10,000       | 16 %     |
| Other income                               | 123,000                      | 115,000      | 8,000        | 7 %      |
|  | 196,000                      | 178,000      | 18,000       | 10 %     |
| Income before provision for income taxes   | 6,333,000                    | 10,281,000   | (3,948,000 ) | -38 %    |
| Provision for income tax (expense)         | (2,343,000 )                 | (3,923,000 ) | 1,580,000    | -40 %    |

Edgar Filing: MEDIFAST INC - Form 10-Q

|  |             |             |                |     |   |
|--|-------------|-------------|----------------|-----|---|
| Net income                                 | \$3,990,000 | \$6,358,000 | \$(2,368,000 ) | -37 | % |
| <p>% of revenue</p>                        |             |             |                |     |   |
| Gross Profit                               | 75.1        | %           | 76.3           | %   |   |
| Selling, general, and administrative costs | 68.2        | %           | 62.7           | %   |   |
| Income from Operations                     | 6.9         | %           | 13.6           | %   |   |

Revenue: Revenue increased to \$88.9 million in the first quarter of 2012 compared to \$74.3 million in the first quarter of 2011, an increase of \$14.6 million or 20%. The Take Shape for Life sales channel accounted for 59.6% of total revenue, Medifast Direct channel accounted for 25.4%, and Weight Control Centers and Medifast Wholesale Physicians accounted for 15% of total revenue. Take Shape for Life sales, which are fueled by increased customer product sales as a result of an increase in active Health Coaches, increased by 12% compared to the first quarter of 2011. As compared to the first quarter of 2011, the Medifast Direct Response sales channel, which is fueled primarily by consumer advertising, increased revenues by approximately 19% year-over year. The Medifast Weight Control Centers and Medifast Wholesale Physicians increased sales by 63% due to the opening of new corporate and franchise locations and year-over-year improvement in same store sales.



Take Shape for Life revenue increased 12% to \$53 million compared with \$47.1 million in 2011. Growth in revenues for the segment was driven by increased customer product sales as a result of an increase in active Health Coaches. The number of active Health Coaches at the end of the first quarter of 2012 increased to 10,200 compared with 10,000 during the period a year ago, an increase of 2%. Active Health Coaches are defined as Health Coaches receiving income from a product sale in the last month of the quarter. The average revenue per health coach per month increased from \$1,600 in the first quarter of 2011 to \$1,650 in the first quarter 2012. The increase of 3% is primarily due additional usage and simplification of training materials, to include the Trilogy Training website that was launched at the Take Shape for Life annual conference in late July. In addition, Take Shape for Life launched an incentive in the month of March 2012 that drove client acquisition and resulted in increasing the monthly revenue per health coach. The Medifast Direct Response Sales division sales increased 19% to \$22.5 million as compared with \$19 million in the first quarter of 2011, an increase of \$3.6 million. Due to a more effective advertising message, more targeted advertising through extensive analytical analysis, and additional public relations success in large national publications, the Company experienced a 2.9 to 1 return on advertising spend during the first quarter of 2012 as compared to a 2.8 to 1 revenue to spend in the first quarter of 2011. The Company spent approximately \$7.85 million on direct response advertising in the first quarter of 2012, an increase of 15% from the first quarter of 2011.

The Medifast Weight Control Centers and Medifast Wholesale Physicians channel represented 15.0% of the Company's overall revenues in the first quarter of 2012. At March 31, 2012, Medifast Weight Control Centers were operating in seventy-five corporate locations in Austin, Dallas, Houston, San Antonio, Orlando, Baltimore, Philadelphia, Delaware, New Jersey, Northern and Southeast Virginia, and South Florida, and thirty-two franchise centers were in operation. In the first quarter of 2012, the Company experienced revenue growth of 63% to \$13.4 million as compared to \$8.2 million in the first quarter of 2011, an increase of \$5.2 million. In the first quarter of 2012, same store sales increased by 21% for corporate Centers open greater than one year. There were 40 centers in the comparative same-store-sales base at March 31, 2012. Throughout 2012, the Company anticipates opening between 25 and 30 corporate owned Medifast Weight Control Centers.

Costs of Sales: Cost of sales increased \$4.6 million in the first quarter of 2012 to \$22.2 million as compared to \$17.6 million in the first quarter of 2011. As a percentage of sales, gross margin decreased to 75.1% from 76.3% in the first quarter of 2011. The decline in gross margin is the result of increased commodity and shipping costs, as well as promotional items introduced in the first quarter of 2012. For the full year 2011, gross margin was 75.3%.

Selling, General and Administrative Costs: Selling, general and administrative expenses were \$60.6 million compared to \$46.6 million in the first quarter of 2011, an increase of \$14 million. As a percentage of sales, selling, general and administrative expenses increased to 68.2% versus 62.7% in the first quarter of 2011. Take Shape for Life commission expense, which is variable based upon product sales, increased by approximately \$3.2 million as TSFL sales grew 12% as compared to the first quarter of 2011. Take Shape for Life Health Coaches are independent contractors that are paid commissions on product sales referred to the Company. Health Coaches earn commissions by referring product sales through their own replicated website or through the Company's in-house call center. The clients of Health Coaches are responsible for order and payment of product and their order is shipped directly to their home or designated address. Health Coaches are not required to purchase product in order to receive a commission. In addition, Health Coaches do not receive a commission on their personal product orders.

Salaries and benefits increased by approximately \$4.4 million in the first quarter of 2012 as compared to last year. The increase in salaries and benefits compared to the first quarter of 2011 is due to the hiring of employees to support new Medifast Weight Control Centers, and new hires in our information technology, human resources, finance, Take Shape for Life, and marketing departments to support growth. Since the beginning of 2011, the Company has opened an additional 36 centers.

In March 2012, the Company recorded restructuring charges of \$723,000 to facilitate a workforce reduction in the Medifast Weight Control Centers and its Corporate offices. Approximately seventy positions were either eliminated or re-aligned in order to enhance the profitability of the MWCC and Wholesale segment. The workforce reduction and staffing re-alignment will result in approximately \$3 million in annualized savings.

Sales and marketing expense increased by \$3.1 million in the first quarter of 2012 as compared to last year. This increase consisted of \$1 million of additional advertising in the Medifast Direct channel, \$1.2 million of branding investments, \$500,000 video production costs, and \$700,000 television and internet advertising in three of the Company's larger markets.

Communication expenses during 2012 were consistent with levels from the first quarter of 2011. Office expenses increased \$1.8 million due to higher rent for administrative offices and Medifast Weight Control Centers, information technology related costs to support our core operating systems, insurance, office expenses primarily at the new centers, and higher accounting fees. Other expenses consisting primarily of depreciation and credit card processing fees increased by \$1.6 million.

**Income taxes:** In the first quarter of 2012, the Company recorded \$2.3 million in income tax expense, an effective rate of 37%. In the first quarter of 2011, the Company recorded \$3.9 million income tax expense, an effective rate of 38.2%. The decline in the effective tax rate was a result of state tax planning performed by the Company. As part of its tax planning process, the Company amended several returns filed in prior years. As a manufacturing entity based in Maryland, the Company adopted the single sales factor apportionment method in addition to claiming new state job credits, reducing the Company's overall effective tax rate compared to the prior year. The Company anticipates a full year tax rate of approximately 36-37% in 2012.

**Net income:** Net income was \$4 million in the first quarter of 2012 as compared to \$6.4 million in the first quarter of 2011, a decrease of \$2.4 million. Pre-tax profit as a percent of sales decreased to 7.1% in the first quarter of 2012 as compared to 13.8% in the first quarter of 2011. The decrease in profitability in the first quarter of 2012 is primarily a result of the expansion of the corporate Medifast Weight Control Centers. The MWCC and Wholesale segment income (loss) before taxes decreased from a gain of \$1.1 million in the first quarter of 2011 to a loss of \$2.2 million in the first quarter of 2012, an overall decrease of \$3.4 million. The decrease is due to additional costs to open new Medifast Weight Control Centers, and support existing centers. Late in the first quarter of 2012, the Company reduced the headcount and re-aligned personnel in the Medifast Weight Control Center division to impact profitability immediately beginning in the second quarter of 2012.

Pre-tax profit in the Medifast segment declined as a percent of sales from 15.8% in the first quarter of 2011 to 13.1% in the first quarter of 2012. The 270 basis points decline in pre-tax profit was as a result of a 120 basis points increase in cost of sales as described above as well as the \$1.2 million advertising expense in Medifast branding testing that equated to 160 basis points of the Medifast segment sales.

**SEGMENT RESULTS OF OPERATIONS****Three Months Ended March 31, 2012 and March 31, 2011**

| Segments           | Net Sales by Segment for the Three Months Ended March 31, |            |               |            |  |
|--------------------|---|------------|---------------|------------|--|
|                    | 2012<br>Sales   | % of Total | 2011<br>Sales | % of Total |  |
| Medifast           | \$ 75,552,000   | 85 %       | \$ 66,097,000 | 89 %       |  |
| MWCC and Wholesale | 13,372,000  | 15 %       | 8,198,000     | 11 %       |  |
| Total Sales        | \$ 88,924,000   | 100 %      | \$ 74,295,000 | 100 %      |  |

Medifast Segment: The Medifast segment consists of the sales from Medifast Direct Marketing and Take Shape for Life. As this represents the majority of our business, this is discussed in the Overview of the Three Months Ended March 31, 2012 compared to Three Months Ended March 31, 2011 above.

The MWCC and Wholesale segment consists of the sales of Medifast Corporate and Franchise Weight Control Centers as well as Medifast Wholesale Physicians. Sales increased by \$5.2 million, or 63% in the first quarter of 2012 as compared to 2011. Revenue increased due to the opening of thirty-one new centers in 2011, as well as a 21% increase in the same store sales for Centers open for greater than one year, and the increased success of franchise centers. The Company's key focus the remainder of 2012 is continuing to enhance the customer experience through additional offerings such as metabolic testing, the support of a dietitian, and a medical review of laboratory tests to show members the impact of weight loss on their overall health. The Company had seventy-five corporate centers in operation as of March 31, 2012 as compared to forty in the prior year. The Company had thirty-two franchise centers in operation as of March 31, 2012 as compared to twenty-one franchise centers in the prior year.

**Three Months Ended March 31, 2012 and March 31, 2011**

| Segments           | Operating Profit by Segment as of March 31, |            |                |            |  |
|--------------------|---|------------|----------------|------------|--|
|                    | 2012<br>Profit                              | % of Total | 2011<br>Profit | % of Total |  |
| Medifast           | \$ 9,879,000                                | 156 %      | \$ 10,414,000  | 101 %      |  |
| MWCC and Wholesale | (2,213,000 )                                | -35 %      | 1,143,000      | 11 %       |  |
| All Other          | (1,333,000 )                                | -21 %      | (1,276,000 )   | -12 %      |  |
| Net Profit         | \$ 6,333,000                                | 100 %      | \$ 10,281,000  | 100 %      |  |

Medifast Segment: The Medifast reporting segment consists of the activity of Medifast Direct Marketing and Take Shape for Life. This represents the majority of our business and is discussed in the Overview of the Three Months Ended March 31, 2012 compared to Three Months Ended March 31, 2011 above. See Note 11, "Business Segments" of the financial statements for a detailed breakout of expenses.

MWCC and Wholesale Segment: Profitability of this segment decreased \$3.4 million in the first quarter of 2012 as compared to the first quarter of 2011. The decrease in net profitability is due to the hiring of expertise in key areas to build the internal infrastructure to open Medifast Weight Control Centers since the first quarter of 2011. Results included a charge of \$388,000 related to workforce reductions in the Centers and Corporate offices. Approximately seventy positions were either eliminated or re-aligned to enhance the profitability of the MWCC and Wholesale segment. Approximately \$2.5 million of annualized savings from restructuring and re-alignment will benefit this segment.

The Company's key focus over the remainder of 2012 is to enhance the customer experience through additional offerings such as metabolic testing, additional dietitian support, and enhanced reviews of laboratory tests to show members the impact of weight loss on their overall health. To improve profitability, the Company is focused on reducing advertising spend as a percentage of sales for each corporate center, focusing on the four-wall staffing strategy of each Corporate Center, and leveraging the corporate support required to operate the Centers. The Company had seventy-five corporate centers in operation as of March 31, 2012 as compared to forty prior to 2011. The Company had thirty-two franchise centers in operation as of March 31, 2012 as compared to twenty-one franchise centers in the prior year.

All Other Segment: The All other segment consists of corporate expenses related to the parent Company operations. Year-over-year parent company expenses increased by \$57,000. Corporate expenses include items such as auditors' fees, attorney's fees, stock compensation expense and corporate governance related to NYSE, Sarbanes Oxley, and SEC regulations. See footnote 11, "Business Segments", for additional detail.

### **Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and a decline in the stock market. The Company does not enter into derivatives, foreign exchange transactions or other financial instruments for trading or speculative purposes. The Company has limited exposure to market risks related to changes in interest rates. The principal risks of loss arising from adverse changes in market rates and prices to which the Company and its subsidiaries are exposed relate to interest rates on debt. Since nearly all of our debt is variable rate based, any changes in market interest rates will cause a similar change in our net interest expense. At March 31, 2012, there was \$4.3 million of variable interest loans outstanding which is subject to interest rate risk. Interest rates on our variable rate loans ranged from 1.54% to 2.24% for the period ended March 31, 2012. Each 100 basis point increase in the bank's LIBOR rates relative to these borrowings would impact interest expense by \$43,000 over a 12-month period.

We are exposed to market risk related to changes in interest rates and market pricing impacting our investment portfolio. Our current investment policy is to maintain an investment portfolio consisting mainly of U.S. money market and high-grade corporate securities, directly or through managed funds. Our cash is deposited in and invested through highly rated financial institutions in North America. Our marketable securities are subject to interest rate risk and market pricing risk and will fall in value if market interest rates increase or if market pricing decreases. If market interest rates were to increase and market pricing were to decrease immediately and uniformly by 10% from levels at March 31, 2012, we estimate that the fair value of our investment portfolio would decline by an immaterial amount and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market conditions on our investments.

### **Item 4. Controls and Procedures**

Management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of March 31, 2012. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported accurately and on a timely basis. Based on this evaluation performed in accordance with the framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, our management concluded that the Company's internal control over financial reporting was effective as of March 31, 2012.

### **Changes in Internal Control over Financial Reporting:**

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended March 31, 2012 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## **Part II Other Information**

### **Item 1. Legal Proceedings**

The Company filed a civil complaint on February 17, 2010 in the U.S. District Court (SD, Cal) against Barry Minkow, his Fraud Discovery Institute, Inc., its subsidiary iBusiness Reporting, its editor William Lobdell, as well as Tracy Coenen, her Sequence, Inc., “Zee Yourself”, and Robert L. Fitzpatrick for defamation and violations of California Corporation Code Sections 25400 et seq and 17200 et seq, alleging a scheme of market manipulation of Medifast stock for Defendants’ monetary gain, by damaging the business reputation of Medifast and its meal replacement weight loss products. Bradley T. MacDonald, former Executive Chairman of Medifast, who was also a large shareholder of the Company, joined the lawsuit individually. The suit seeks at least \$270 million in compensatory damages, punitive damages, and ancillary relief. The Company continues prosecution of this civil suit. The Company also continues to pursue its pending complaints filed in March, 2009 with the SEC, Maryland Securities Commissioner, and the U.S. Attorney against most of these same named defendants with respect to the related matter.

In early 2010, the Chapter 7 Bankruptcy Trustee for Go Fig, Inc. et al., Debtors, filed an adversary civil proceeding in the US Bankruptcy Court (ED, Missouri) against Jason Pharmaceuticals, Inc., a subsidiary of the Company and other unrelated entities seeking to recover, as to each, alleged preferential payments. Jason Pharmaceuticals, Inc. sold product received by the Debtors and has previously filed a pending claim in the same bankruptcy. Medifast disputes the Trustee’s allegations and intends to vigorously defend itself. This action was by Court order placed on hold while the Trustee litigates similar issues against another Party.

Since 2010, Jason Pharmaceuticals, Inc. has received five Notices of Charge of Discrimination filed with the U.S. Equal Employment Opportunity Commission (“EEOC”) alleging discrimination suffered by two current employees and three former employees. The EEOC dismissed three of those charges in 2011. In 2011 the two claimants whose claims were dismissed during the second quarter, filed suit to pursue those claims in U.S. District Court. One of those claims was resolved through mediation recently. The Company intends to vigorously defend against the remaining claim.

On March 17, 2011, a class action complaint titled Oren Proter et al. v. Medifast, Inc. et al. (Civil Action 2011-CV-720[BEL]), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-5 promulgated under the Exchange Act, was filed for an unspecified amount of damages in the U.S. District Court, District of Maryland. The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material adverse facts regarding the Company’s business, operations and prospects. On March 24, 2011, a class action complaint titled Fred Greenberg v Medifast, Inc., et al (Civil Action 2011-CV776 [BEL], alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule

10b-5 promulgated under the Exchange Act, was filed for an unspecified amount of damages in the U.S. District Court, District of Maryland. The complaint alleges that the defendants made false and/or misleading statements and failed to disclose material adverse facts regarding the Company's business, operations and prospects. On July 19, 2011, the U.S. District Judge ordered the consolidation of the cases and appointment of co-lead counsel among other matters. The Greenberg case was dismissed without prejudice. The Plaintiffs subsequently filed an Amended Complaint. The Company has reviewed these allegations, and subsequently filed a Motion to Dismiss which is currently pending. The Company intends to vigorously defend against this amended complaint.



On April 1, 2011, a shareholder derivative complaint titled Shane Rothenberger, derivatively on behalf of Medifast, Inc., v Bradley T. MacDonald et al. (Civil Action 2011-CV 863 [BEL]); and on April 11, 2011, a shareholder derivative complaint titled James A. Thompson, derivatively on behalf of Medifast, Inc., v Bradley T. MacDonald et al. (Civil Action 2011-CV934 [BEL]) were filed in the U.S. District Court, District of Maryland. The identically worded complaints allege breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. Each complaint requests an unspecified amount of damages, a Court Order directing reformation of corporate governance, restitution to the Company and payment of costs and disbursements. The Company is named as a nominal defendant. On July 19, 2011, the U.S. District Judge ordered consolidation of the two cases, appointment of co-lead counsel, and the filing of a consolidated complaint, among other matters. No response is due from the Company at this time. After the consolidated complaint is filed, the Company intends to take whatever action it deems necessary to protect its interests.

#### **Item 1A. Risk Factors**

Information about risk factors for the three months ended March 31, 2012, does not differ materially from those in set forth in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2011.

#### **Item 5. Other Information**

The Board of Directors of Medifast, Inc. authorized the repurchase of up to 500,000 shares of the Company's common stock as approved by Board consent on July 21, 2011. The authorization remains open for a period of 24 months ending on July 21, 2013.

Stock repurchases under this program may be made by the Broker through open market and privately negotiated transactions at times and in such amounts as management shall deem appropriate pursuant to Rule 10b-18 of the Exchange Act. The timing and actual number of shares which may be repurchased will depend on a variety of factors including price, corporate authorization provisions, above noted regulatory requirements, and other market conditions.

We are not obligated to purchase any shares. Subject to applicable securities laws repurchases may be made at such times and in such amounts, as our management deems appropriate. The share repurchase program may be discontinued or terminated at any time and we have not established a date for completion of the share repurchase program. The repurchases will be funded from our available cash.

There are 275,000 remaining authorized shares that may be repurchased.

The following is a summary of our common stock purchases during the quarter ended March 31, 2012:

| Period                         | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs |
|--------------------------------|----------------------------------|------------------------------|--|--|
| January 1 - January 31, 2012   | -                                | -                            | -  | 275,000  |
| February 1 - February 29, 2012 | -                                | -                            | -  | 275,000  |
| March 1 - March 31, 2012       | -                                | -                            | -  | 275,000  |

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **Medifast, Inc.**

BY:/S/ MICHAEL C. MACDONALD May 10, 2012

Michael C. MacDonald  
Executive Chairman of the Board and Chief  
Executive Officer  
(principal executive officer )

BY:/S/ BRENDAN N. CONNORS May 10, 2012

Brendan N. Connors  
Chief Financial Officer  
(principal financial officer)

Index to Exhibits

| Exhibit Number | Description of Exhibit  |
|----------------|---|
| 31.1           | Certification of Chief Executive Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2           | Certification of Chief Financial Officer pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1           | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                |